and discontinuation of infusions before life-threatening GVHD has developed. Donor lymphocyte infusions (DLI) were given between Keywords: chronic myeloid leukemia; graft-versusJune 1990 and March 1996 to 18 patients with chronic leukemia; donor lymphocyte infusions myeloid leukemia (CML) for the treatment of cytogenetic (n ‫؍‬ 6) or hematologic relapse (n ‫؍‬ 12) following an allogeneic bone marrow transplant (BMT). Patients were divided in two groups: patients in group A (n ‫؍‬ 8)
Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation
, 2 ؋ 10 7 /kg, 2 ؋ 10 6 /kg, and patients to a high risk of leukemic relapse, 2 and this has 2 ؋ 10 5 /kg, respectively (P ‫؍‬ 0.01). Median transaminnow been shown in very large numbers of patients. 1, 2 ase levels were found to be significantly increased in If mature donor T cells infused on the day of marrow patients with, as compared to patients without, acute transplant (an average of 6 × 10 7 /kg) have such an GVHD (GPT 412 vs 28 IU/l; P ‫؍‬ 0.03). Severe aplasia important role in preventing relapse, the use of large numoccurred in four and was a contributing cause of death bers of donor T cells which have undergone maturation in in two patients. Overall, four patients died as a consethe donor thymus, would possibly be helpful in treating quence of DLI and all received Ͼ1 ؋ 10 8 /kg cells: the relapse. Indeed this has been shown to be the case, actuarial risk was 38% in group A and 14% in group especially in patients with chronic myeloid leukemia B (P ‫؍‬ 0.1). There were 10 complete and three partial (CML), both for unfractionated 7-17 and CD8-depleted cytogenetic responses: the actuarial probability at 5 cells.
18 years of being Ph negative was 69%: it was 46% for The exact mechanism by which the leukemic clone can group A and 85% for group B (P ‫؍‬ 0.1). The longest be reduced is unknown. GVHD has a deleterious effect on patient is now 6 years post-DLI, Ph negative, BCR-ABL hematopoietic cells 19, 20 and it is quite possible that the sonegative. The actuarial 3 year survival is 38% in group called GVL effect seen in humans is an allo-effect mediated A and 86% in group B (P ‫؍‬ 0.06). The study confirms by donor T cells recognizing minor differences between that DLI post-BMT is not innocuous and that there is a donor and recipient: 7 this would lead to cytotoxicity against definite long-lasting antileukemic effect in patients with recipient leukemic cells, and would spare donor hemo-CML. It also suggests that: (1) the risk of developing poietic progenitors. The consequence would be induction GVHD correlates with the number of infused cells; (2) of remission, also maintained over time, suggesting that significant elevations of serum GPT levels are assoengraftment and expansion of infused donor T cells. ciated with GVHD; and (3) that the use of escalating
In the present study we report 18 patients who were doses of cells may allow the identification of side-effects given donor lymphocyte infusions (DLI) either for prophylaxis or treatment of leukemia relapse following allogeneic BMT: we describe two groups of patients, the first given large numbers of donor cells and the second given escalat- Table 1 : 12 had hematologic relapse days 127 and 148. If acute GVHD developed the program (chronic phase n = 5; accelerated phase n = 6; blastic transwas stopped. formation n = 1) and six had cytogenetic relapse at the time of DLI.
Statistical analysis Transplant procedures
2 and Student's t-tests were used to analyze the data. Conditioning therapy consisted of cyclophosphamide Kaplan-Meier plots were used to analyze survival data. (120 mg/kg) followed by a 2-day rest and fractionated total body irradiation (TBI) (3.3 Gy/day on each of 3 consecutive days. Patients receiving T cell-depleted marrow were Results prepared with single dose TBI 7.5 Gy on day −7, thiotepa 5 mg/kg on day −6, Campath 1G 20 mg i.v. on days −5, −4, −3, −2 and −1, CY 50 mg/kg on days −3 and −2 and Donor lymphocyte infusions (DLI) marrow treated with Campath 1M. Campath 1G and Campath 1M were kindly provided by Prof H Waldman and Dr DLI were given between days +182 and days +2545 post-BMT and between 3 and 2231 days after relapse (Table 1 ). G Hale, Cambridge, UK.
There were no immediate reactions, except in one patient receiving cryopreserved cells, who had a serious allergic GVHD prophylaxis reaction with respiratory problems, which resolved on highdose intravenous prednisolone. The first group of patients Patients receiving unmanipulated marrow were all given cyclosporin A (CsA) with methotrexate. Patients receiving (n = 8, group A) received the entire leukapheresis product (range 1-2 × 10 8 cells/kg): the median number of infusions T cell-depleted marrow were not given in vivo immunosuppression post-BMT.
in this group was two (range 1-3). The second group of patients (n = 10) received a median number of seven infusions (range 3-9). In this group, patients were designed Donor lymphocyte infusions (DLI) to receive escalating doses of DLI starting from 2 × 10 5 /kg up to 2 × 10 8 /kg: three patients received the programmed Donors were the same as donated marrow. They underwent leukapheresis on a cell separator. In a first group of eight eight infusions, six patients stopped at 2 × 10 7 cells/kg and one patient at 2 × 10 6 cells/kg because of acute GVHD. patients, the entire leukapheresis cells were infused without BMT = bone marrow transplantation; Acc = accelerated; CP = chronic phase; BT = blastic transformation; TCD = T cells depletion; DLI = donor lymphocytes infusion; CML = chronic myeloid leukemia; HEM = hematological; CYTO = cytogenetic.
Acute GVHD Mortality due to DLI
The actuarial incidence of acute GVHD was 67%. GVHD Overall, four patients died as a consequence of DLI and all developed in 7/19 (37%) infusions of у1 × 10 8 cells/kg, received у1 × 10 8 /kg cells: three deaths occurred in group in 4/28 (14%) infusions of 2 × 10 7 cells/kg, in 1/21 (5%) A (eight patients) and one in group B (10 patients). The infusions of 1 × 10 6 cells/kg and in 0/12 infusions of actuarial risk of treatment-related mortality (TRM) was 2 × 10 5 /kg (P = 0.01) (Figure 1 ). GVHD was scored as 38% in group A and 14% in group B (P = 0.1). grade I, II, III respectively in four, four, four ( Table 2 ). All patients were off CsA at the time of DLI, but six had to be started on CsA and/or prednisolone. Death due to Graft-versus-leukemia (GVL) aGVHD was seen in three patients (two in group A): all of these had received a dose of cells equal to or exceeding An antileukemic effect was seen in the 18 CML patients 1 × 10 8 /kg. with 10 complete and three partial cytogenetic and/or hematologic responses; four patients did not respond, one patient was unevaluable because of severe aplasia which Transaminase levels prevented cytogenetic analysis. Of the 12 hematologic relapses six (50%) had a complete response, compared to GOT and GPT levels were scored and found to be elevated 4/6 (66%) complete responses in patients with cytogenetic in patients with aGVHD: the median maximum GPT level relapse (P = 0.4 in Fisher's exact test). The median duration (IU/ml) was 412 (range 35-1860) for patients with aGVHD of response is 18 months (range 8-72). The actuarial probvs 28 (range 13-54) for patients without aGVHD ability of becoming Ph negative was 69% at 6 years, with (P = 0.03). Similarly, of the nine patients with elevated a median interval of 10 months between the first DLI and GPT levels, eight had acute GVHD.
cytogenetic response (Figure 2 ).
Pancytopenia
Overall survival Severe aplasia occurred in four patients and was a contributing cause of death in two (all in group A). Pancytopenia
The overall survival of the whole group was 52% at 60 months; 86% in group B and 38% in group A (P = 0.06) was severe in all four patients and lasted 2, 3, 4 and 8 months, respectively. The last patient was dependent on (Figure 3) . The median follow-up for surviving patients is 960 days (range 433-2221). The longest survivor is over 6 platelet and red blood cell transfusions for 8 months and then slowly showed hematologic recovery: she is now 1 years post-DLI: this patient relapsed 334 days after unmanipulated BMT, was given one single DLI in July 1990, and year after recovery with normal blood counts and is Ph negative.
is now BCR-ABL negative (March 1996). aGVHD = acute graft-versus-host disease; Ph = Philadelphia chromosome; A = alive; D = dead; Infec = infection; Leuk = leukemia; IP = interstitial pneumonia; FU = follow-up. the large number of patients who could be treated with DLI: close to 700 CML patients are being allografted every year in Europe: 21 if 50% survive the transplant and 25% of these relapse, there will have been approximately 800 relapses in the past 10 years. A large number of these patients may still be alive, and would thus be eligible for DLI, with a change of success in the order of 50%. It is interesting that one of our CML patients was successfully treated 1192 days after relapse and is now Ph negative. In the future we can expect to treat an increasing number of cytogenetic relapses with an even higher success rate.
Despite convincing evidence in animals of strong GVL activity in acute leukemia, 3, 4, 6 clinical data, so far reported, suggest a significantly higher chance of cure in patients with CML as compared to patients with acute leukemia. 16 The reasons for this difference are unknown: possible explanations include a preferential expression on CML cells of potential target antigens, such as minor or major histocompatibility antigens. If GVL is an allo-effect, as has been shown to enrich for CML precursors. 22 Cytotoxic T cell clones specific to recipient alloantigens have been demonstrated in patients with GVHD: 23 it is very important Discussion to prove their presence in patients responding to DLI. A second hypothesis for the different effect of DLI in CML In this study we have confirmed that excellent results can be achieved using donor lymphocytes to treat CML relapse would be a smaller number of clonogenic cells in this disease, following recent studies indicating that the majority after allogeneic BMT. 7 We have also shown that: (1) the risk of developing acute GVHD correlates with the number of early precursors (LTC-IC) in patients presenting with CML, are Philadelphia chromosome negative. 24 There is of infused cells; (2) that the use of escalating doses of cells may allow the identification of side-effects and discontinuone additional difference: patients with CML are often given DLI with or after interferon, and this may well have ation of infusions; and (3) that significant elevations of serum GPT levels are associated with GVHD and may be an immune-modulating effect, although the European combined data did not suggest a significant impact of IFN on used to monitor alloreactivity.
As to the antileukemic effect, this was very clear in response.
16
The anti-leukemia effect of DLI is often associated with patients with cytogenetic relapse and, most interestingly, also in patients with hematologic relapse, in keeping with GVHD, and the latter can be life-threatening. In the first group of eight patients receiving the entire leukapheresis the European data. 16 One patient had hematologic relapse with an additional chromosomal abnormality, and still had product, three died, two with cytopenia, one with over-
